Keywords: Merck & Co, Boceprivir, Hepatitis C, USA, EU, Expedited review, Vertex

Merck & Co’s hep C drug candidate boceprevir gets expedited review in USA and EU

Article | 07 January 2011

Print This

US drug giant Merck & Co (NYSE: MRK) says that regulatory applications for its investigational oral hepatitis C virus (HCV) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in